Elan Stock Keeps Rising Despite Denial of BMS Takeover
Bristol-Myers Squibb dismissed it as “rumors and speculation.” Elan declines to comment. And UBS says BMS has it has “confirmed” that it isn’t happening. Yet Elan’s stock continues to float on the idea that BMS is about to buy some or all of the company.
As the graphic shows (click to enlarge), Elan’s stock rose from around 6.70 to more than 7.50 over the weekend after reports in the WSJ and Reuters on Sunday said BMS was considering a hookup with Elan.
But on Monday morning, both UBS and BMS poured cold water on the idea. Bloomberg:
“BMY has confirmed to us that it is not currently in talks to buy a minority stake in Elan,” Roopesh Patel and Keyur Parekh, New York-based analysts for UBS, wrote in a report today.
Brian Henry, a spokesman for New York-based Bristol-Myers, said in an e-mail the company had “no comment on rumors and speculation.”
The UBS quote leaves some wiggle room: it refers to a “minority stake” rather than an outright acquisition.
Elan has primed the market to believe it is a takeover target. It announced a strategic review in January that included a merger or sale. It was recently the subject of bogus rumors that Lundbeck wanted to buy it.
Anyone kicking the tires at Elan will want to ask some questions about the company’s bizarre management structure. The top execs are based thousands of miles apart, in Ireland, Pennsylvania and California. The company just added a chief commercial officer — in South San Francisco.
Renee Tannenbaum’s new office is a mere 5,000 miles from CEO Kelly Martin’s in Dublin. That’s eight time zones away. Put another way, just as Tannenbaum arrives at her desk at 9 a.m. San Francisco time, Martin is turning out the lights in his Dublin office where it’s 5 p.m.
Conspicuous by its silence is Jack Schuler’s FixElan.com. The angry investor, who wants to see management ousted at the company, hasn’t updated his site since February.
- Previous BNET coverage of Elan:
- Elan Silent on Corporate Jets as 230 Are Laid Off
- Elan Management Creates Self-Enrichment Plan as Pfizer-Wyeth Deal Threatens Bapineuzumab
- Elan Chairman: “We’re Qualified Managers Because We’re Irish”
- Elan Sees Problems on Alzheimer’s Drug; Puts Itself Up for Sale
- Elan “Poison Pill” Deal With Biogen Prevents Rumored Pfizer Takeover
- Elan’s Pennsylvania Lawyer Once Again Makes News
- Elan CEO Martin’s Pay Cut by Half
Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.
BNET User Analysis